| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
DRUG DEVELOPMENT |
From Clinical Pharmacology, Wyeth Research, Collegeville, Pennsylvania.
Drug absorption is a very complex process that manifests itself through potential interaction with a host of physicochemical and physiological variables. Some factors that may affect the absorption processes include presystemic metabolism/efflux, the "absorption window" along the gastrointestinal tract, disease states, demographics (gender, age, ethnicity), and biopharmaceutical classification of solid dosage forms. Despite the complexity of the absorption processes, the analysis of the absorption kinetic data is mostly empirical, and the assumption of first-order absorption is axiomatic. Nevertheless, we often encounter irregular drug absorption profiles (such as double-peak, absorption window-type absorption profiles, etc.) that cannot be satisfactorily described by a simple first-order absorption process. The selection of an inappropriate absorption model would result in the misspecification of the pharmacokinetic model and subsequent erroneous prediction of the dosing regimen. This article presents several pharmacokinetic strategies in analyzing typical and atypical absorption profiles. The atypical absorption profiles discussed in this article include parallel first-order absorption, mixed zero-order and first-order absorption, Weibull-type absorption, absorption window with or without Michaelis-Menton absorption, time-dependent absorption, and inverse Gaussian density absorption. In any event, intravenous drug concentration-time data are generally needed to avoid the ambiguousness in the absorption analyses.
This article has been cited by other articles:
|
|
 |
|
  L. Rosso, C. S. Brock, J. M. Gallo, A. Saleem, P. M. Price, F. E. Turkheimer, and E. O. Aboagye A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients Cancer Res., January 1, 2009; 69(1): 120 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, M. Weiss, and D. Z. D'Argenio A Note on Population Analysis of Dissolution-Absorption Models Using the Inverse Gaussian Function J. Clin. Pharmacol., June 1, 2008; 48(6): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Landberg, A.-M. Linko, A. Kamal-Eldin, B. Vessby, H. Adlercreutz, and P. Aman Human Plasma Kinetics and Relative Bioavailability of Alkylresorcinols after Intake of Rye Bran J. Nutr., November 1, 2006; 136(11): 2760 - 2765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dutta and R. C. Reed A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets. J. Clin. Pharmacol., August 1, 2006; 46(8): 952 - 957. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dutta, R. C Reed, and R. F O'Dea Comparative Absorption Profiles of Divalproex Sodium Delayed-Release Versus Extended-Release Tablets--Clinical Implications Ann. Pharmacother., April 1, 2006; 40(4): 619 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhou, P. R. Mayer, J. Wajdula, and S. Fatenejad Unaltered Etanercept Pharmacokinetics With Concurrent Methotrexate in Patients With Rheumatoid Arthritis J. Clin. Pharmacol., November 1, 2004; 44(11): 1235 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lee, M. Hossain, Y. Wang, and G. Sedek Absorption of Rivastigmine from Different Regions of the Gastrointestinal Tract in Humans J. Clin. Pharmacol., June 1, 2004; 44(6): 599 - 604. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
